Transcranial Doppler in Children With Hemoglobinopathies

Status Not yet recruiting

Clinical Trial Summary

Transcranial Doppler ultrasonography (TCD) is a noninvasive, portable technique for evaluating the intracranial vasculature. TCD ultrasonography is performed placing a low frequency (≤ 2 MHz) transducer on the scalp of the patient, in order to visualize the intracranial arterial vessels through specific acoustic windows, where bone is thinner, and evaluate cerebral blood flow velocity (CBFV) . Patients diagnosed to have hemoglobinopathy conditions with its most common forms thalassemia and sickle cell disease manifest both biochemical and clinical evidence of hypercoagulability conditions include deep venous thrombosis, pulmonary emboli and recurrent arterial occlusion . Cerebrovascular accidents can be identified using transcranial Doppler ultrasonography which enables evaluation of cerebral artery blood flow velocity with a sensitivity of 90% and specificity of 100 % when compared with cerebral angiography . According to the stroke prevention trial in sickle cell anemia (STOP) study ,TCDs were classified based on blood velocity in the circle of Willis, expressed as time averaged mean of the maximum velocity (TAMMV). Children with abnormal, high velocities (>200cm/s) were at increased risk of stroke, which was reduced by 90% after starting regular blood transfusions. TAMMVs less than 170cm/s were classified as normal with annual TCD scanning recommended, whereas velocities between 170 and 200cm/s were called conditional, and followed up more closely without starting transfusion.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hemoglobinopathies

Clinical Trial Details

NCT number	NCT04798157
Study type	Interventional
Source	Sohag University
Contact	Mohamed E. Mohamed, ass. teacher
Phone	+201030826466
Email	mohammad.albadry2012@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	April 2021
Completion date	October 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Recruiting	`NCT06107400` - Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease	Early Phase 1
Enrolling by invitation	`NCT02986698` - In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)	Phase 1
Completed	`NCT00744692` - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders	Phase 1
Recruiting	`NCT05799118` - Study of the Role of Genetic Modifiers in Hemoglobinopathies
Active, not recruiting	`NCT03745287` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease	Phase 2/Phase 3
Completed	`NCT00673608` - Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload	Phase 4
Recruiting	`NCT04644016` - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders	Phase 2
Recruiting	`NCT04853576` - A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)	Phase 1/Phase 2
Recruiting	`NCT05356195` - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)	Phase 3
Completed	`NCT03609840` - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Active, not recruiting	`NCT01850108` - Non-Myeloablative Conditioning and Bone Marrow Transplantation	N/A
Recruiting	`NCT05329649` - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)	Phase 3
Active, not recruiting	`NCT01966367` - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation	Phase 1/Phase 2
Completed	`NCT00153985` - Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies	Phase 2
Recruiting	`NCT03128996` - Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders	Phase 1/Phase 2
Completed	`NCT03149289` - Hepatitis C Virus Infection in Patients With Hemoglobinopathies	N/A
Completed	`NCT00000588` - Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone	Phase 2